title: Overexpression of CD39 and high tumoral CD39⁺/CD8⁺ ratio are associated with adverse prognosis in resectable gastric cancer.
abstract: CD39/ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1) is a cell surface-located, rate-limiting enzyme in the generation of adenosine, and plays a crucial role in tumor development. We examined co-expression of CD39 and CD8in gastric cancer (GC) and showed that the expression of CD39 and CD8 increased significantly in tumor tissues compared to paired peritumor tissues. The expression of tumoral CD39 (tCD39), but not tumoral CD8 (tCD8), was related to overall survival. Furthermore, the CD39(+)/CD8(+) ratio was associated with poor prognosis in resected GC patients. Taken together, our data indicate that highCD39 expression and high tCD39(+)/CD8(+) ratio in GC is a predictor of poor prognosis for GC patients after radical resection. Moreover, CD39 could serve as a potential target for cancer immunotherapy.
authors.affiliation: Department of General Surgery, Gongli Hospital Shanghai, China.
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Cai
authors.affiliation: Department of General Surgery, Zhongshan Hospital, Fudan University Shanghai, China.
authors.forename: Xue-Fei
authors.initials: XF
authors.lastname: Wang
authors.affiliation: Department of General Surgery, Gongli Hospital Shanghai, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of General Surgery, Gongli Hospital Shanghai, China.
authors.forename: Jiang-Nan
authors.initials: JN
authors.lastname: Dong
authors.affiliation: Department of General Surgery, Gongli Hospital Shanghai, China.
authors.forename: Jiang-Qi
authors.initials: JQ
authors.lastname: Liu
authors.affiliation: Department of General Surgery, Gongli Hospital Shanghai, China.
authors.forename: Neng-Ping
authors.initials: NP
authors.lastname: Li
authors.affiliation: Department of General Surgery, Gongli Hospital Shanghai, China.
authors.forename: Bei
authors.initials: B
authors.lastname: Yun
authors.affiliation: Department of General Surgery, Gongli Hospital Shanghai, China.
authors.forename: Rong-Long
authors.initials: RL
authors.lastname: Xia
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis; D001081:Apyrase / Q000032:analysis / Q000096:biosynthesis; D014408:Biomarkers, Tumor / Q000032:analysis / Q000276:immunology*; D016827:CD8 Antigens / Q000032:analysis / Q000096:biosynthesis; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology*
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; D016827:CD8 Antigens; D001081:Apyrase; C067869:CD39 antigen
keywords: CD39; gastric cancer; prognosis; tCD39+/CD8+ ratio
references.citation: Cancer Res. 1998 Aug 15;58(16):3491-4
references.pmid: 9721846
references.citation: J Allergy Clin Immunol. 2009 Jun;123(6):1287-96.e2
references.pmid: 19427686
references.citation: J Cancer Res Clin Oncol. 2010 Oct;136(10):1585-95
references.pmid: 20221835
references.citation: Clin Cancer Res. 2004 Jul 1;10(13):4450-6
references.pmid: 15240536
references.citation: Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):367-72
references.pmid: 21816376
references.citation: Nat Med. 1999 Sep;5(9):1010-7
references.pmid: 10470077
references.citation: Purinergic Signal. 2007 Mar;3(1-2):171-80
references.pmid: 18404431
references.citation: Trends Immunol. 2004 Jul;25(7):374-80
references.pmid: 15207505
references.citation: Gastroenterology. 2010 Sep;139(3):1030-40
references.pmid: 20546740
references.citation: Immunity. 2004 Aug;21(2):137-48
references.pmid: 15308095
references.citation: Am J Transplant. 2010 Nov;10(11):2410-20
references.pmid: 20977632
references.citation: Clin Exp Immunol. 2014 Aug;177(2):531-43
references.pmid: 24749746
references.citation: Prostate. 2014 Oct;74(14):1452-61
references.pmid: 25111810
references.citation: Cancer Res. 2001 Jul 1;61(13):5132-6
references.pmid: 11431351
references.citation: Immunol Cell Biol. 1993 Dec;71 ( Pt 6):571-81
references.pmid: 8314284
references.citation: Oncoimmunology. 2015 May 22;4(6):e1002726
references.pmid: 26155410
references.citation: J Immunol. 2009 Nov 15;183(10):6157-66
references.pmid: 19864600
references.citation: Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G223-30
references.pmid: 16920697
references.citation: Int J Infect Dis. 2015 Jan;30:57-63
references.pmid: 25461658
references.citation: J Immunol Methods. 2009 Jul 31;346(1-2):55-63
references.pmid: 19450601
references.citation: Gastroenterology. 2014 Nov;147(5):1043-54
references.pmid: 25046164
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
references.pmid: 16344461
references.citation: Blood. 2005 Jun 15;105(12):4707-14
references.pmid: 15746085
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
references.pmid: 17360651
references.citation: Blood. 2007 Aug 15;110(4):1225-32
references.pmid: 17449799
references.citation: J Exp Med. 2007 Jun 11;204(6):1257-65
references.pmid: 17502665
references.citation: Cancer Res. 2001 May 15;61(10):3932-6
references.pmid: 11358808
references.citation: Int Rev Cytol. 1995;158:141-214
references.pmid: 7721538
references.citation: J Clin Invest. 1997 Mar 15;99(6):1351-60
references.pmid: 9077545
references.citation: Clin Exp Dermatol. 2015 Mar;40(2):182-91
references.pmid: 25284153
references.citation: J Autoimmun. 2015 Apr;58:12-20
references.pmid: 25640206
references.citation: Purinergic Signal. 2011 Jun;7(2):231-41
references.pmid: 21484085